GLP-1

GLP-1
Name	Glucagon-like peptide-1
Organism	Homo sapiens

GLP-1 is a critical incretin hormone primarily secreted by enteroendocrine L-cells in the distal ileum and colon following nutrient ingestion. It plays a central role in glucose homeostasis by enhancing glucose-dependent insulin secretion from pancreatic beta cells. The hormone's multifaceted actions extend to appetite regulation and gastric emptying, making it a pivotal target for metabolic disease therapeutics.

Structure and function

The bioactive form is derived from proglucagon through post-translational modification mediated by prohormone convertase 1 within intestinal cells. This peptide hormone exerts its effects by binding to the specific GLP-1 receptor, a G protein-coupled receptor widely expressed in tissues including the pancreas, brain, heart, and gastrointestinal tract. The interaction initiates intracellular signaling cascades, primarily involving cyclic AMP and protein kinase A, which modulate cellular functions. Research from institutions like the University of Copenhagen has been instrumental in elucidating these fundamental mechanisms.

Physiological effects

Its primary physiological role is to potentiate glucose-stimulated insulin secretion from the islets of Langerhans, a process vital for postprandial glucose control. Concurrently, it suppresses the release of glucagon from pancreatic alpha cells, reducing hepatic glucose production. Beyond the pancreas, it delays gastric emptying and promotes satiety through actions on the hypothalamus and brainstem, as studied in facilities like the National Institutes of Health. These integrated effects collectively lower blood glucose with a low risk of hypoglycemia.

Therapeutic applications

Given its glucose-lowering and weight-modulating properties, it has become a cornerstone for managing type 2 diabetes mellitus. The development of degradation-resistant analogs has led to effective treatments that improve glycated hemoglobin levels. Furthermore, these therapies are approved for obesity management by regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency. Ongoing investigations explore its potential benefits in cardiovascular disease, non-alcoholic steatohepatitis, and neurodegenerative disorders like Alzheimer's disease.

Receptor agonists and analogs

To overcome rapid inactivation by the enzyme dipeptidyl peptidase-4, several long-acting GLP-1 receptor agonists have been developed. These include exenatide, derived from the Gila monster lizard, and human analogs like liraglutide and semaglutide, created by companies such as Novo Nordisk. More recent agents like tirzepatide, developed by Eli Lilly and Company, act as dual agonists at both the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, offering enhanced efficacy.

Endogenous regulation and degradation

Secretion is stimulated by the presence of nutrients, particularly carbohydrates and fats, in the intestinal lumen. The hormone has an extremely short plasma half-life of approximately two minutes due to rapid cleavage by dipeptidyl peptidase-4, an enzyme expressed on the surface of endothelial cells in the capillaries. This rapid degradation limits its native therapeutic utility, necessitating the development of stable analogs or the use of dipeptidyl peptidase-4 inhibitors like sitagliptin to prolong the action of the endogenous hormone.

Research and clinical development

Current research, supported by organizations like the American Diabetes Association, extends beyond metabolic control to examine cardioprotective and renoprotective effects observed in large outcomes trials such as LEADER and SUSTAIN-6. Investigations into oral formulations, novel delivery systems, and combination therapies with other hormones like amylin are actively pursued. The field continues to evolve with research into gene therapy approaches and the exploration of its role in inflammation and cognitive function.

Category:Peptide hormones Category:Diabetes Category:Endocrinology